The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.
 
Patrick Wayne Cobb
Stock and Other Ownership Interests - Amgen; Boston Scientific; crispr therapeutics; Intuitive Surgical; Johnson & Johnson; Moderna Therapeutics; United Health Group
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Altor BioScience (Inst); Aptose Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BeiGene (Inst); Blue Note Therapeutics (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Decibel Therapeutics (Inst); Galera Therapeutics (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Incyte (Inst); Innocare (Inst); Innovent Biologics (Inst); Ipsen (Inst); Isofol Medical (Inst); Lilly (Inst); Loxo (Inst); MEI Pharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Tolmar (Inst); Veloxis (Inst); Viracta Therapeutics (Inst); XBiotech (Inst)
 
Heng Zhou
Employment - Merck
 
Akash Nahar
Employment - Merck
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme